Literature DB >> 21442799

Effect of HIV protease inhibitors and Orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis.

Anindita Majumdar1, Gauri Wankhade, Pranita D Kamble, B C Harinath.   

Abstract

BACKGROUND: Mycobacterial excretory secretory-31 (SEVA TB ES-31) antigen is shown to possess protease and lipase activities. AIM: To study the effect of commonly used HIV-protease inhibitors and lipase inhibitor Orlistat if any on mycobacterial ES-31 serine protease in vitro enzyme activity and on the growth of M.tb H37Ra bacilli in axenic culture.
METHODS: Effect of HIV-protease inhibitors namely Ritonavir, Lopinavir and Indinavir and Orlistat on protease activity of ES-31 was assessed using azocasein assay and on bacillary growth in axenic culture of Mycobacterium tuberculosis H37Ra. The concentration of ES-31 antigen in culture filtrate was determined by sandwich peroxidase ELISA using anti ES-31 antibody and the growth of bacilli by CFU count.
RESULTS: HIV-protease inhibitors such as Ritonavir, Lopinavir and Indinavir and lipase inhibitor Orlistat inhibited serine protease activity by 41.3 - 69.7% in vitro. These inhibitors also showed decreased bacterial growth in axenic culture and further confirmed by decreased concentration of ES-31 serine protease secretion in the culture fluid. Ritonavir showed maximum inhibition of 77% on the growth of the bacilli in axenic culture while anti obesity drug Orlistat showed 61% inhibition.
CONCLUSION: SEVA TB ES-31 with serine protease and lipase activities may be a potential drug target in tuberculosis management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21442799

Source DB:  PubMed          Journal:  Indian J Tuberc        ISSN: 0019-5707


  2 in total

1.  Effects of Lipid-Lowering Drugs on Vancomycin Susceptibility of Mycobacteria.

Authors:  Céline Rens; Françoise Laval; Mamadou Daffé; Olivier Denis; Rosangela Frita; Alain Baulard; Ruddy Wattiez; Philippe Lefèvre; Véronique Fontaine
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Early Lesion of Post-Primary Tuberculosis: Subclinical Driver of Disease and Target for Vaccines and Host-Directed Therapies.

Authors:  Robert E Brown; Robert L Hunter
Journal:  Pathogens       Date:  2021-12-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.